Evidence mapPaperPMID 40335342Full record

SynthesisThe journal of prevention of Alzheimer's disease2025

A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care.

Mary Tullipan, Johnson George, Parker Magin, Kali Godbee, Jane Ferns, Claire Frewin

Abstract readSystematic Review
In one paragraph

Synthesis in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mary TullipanCentre for Medicine Use and Safety, Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Victoria, Australia. Electronic address: mary.tullipan@monash.edu.
Johnson GeorgeCentre for Medicine Use and Safety, Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Victoria, Australia & School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, St Kilda, Victoria, Australia.
Parker MaginSchool of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
Kali GodbeeCentre for Medicine Use and Safety, Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Victoria, Australia.
Jane FernsDepartment of Rural Health, University of Newcastle, Taree, New South Wales, Australia.
Claire FrewinDepartment of Rural Health, University of Newcastle, Taree, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathological changes of dementia are thought to commence in mid-life, making mid-life an attractive target for dementia risk reduction. This review assessed the current literature on multidomain dementia risk-reduction interventions in mid-life.

methodsWe systematically searched MEDLINE, CINAHL and EMBASE for eligible studies. Studies were included if (i) participants had a mean age between 45 and 65 years, (ii) the intervention was delivered in a primary care setting and targeted two or more dementia risk factors, and (iii) outcomes were change in cognitive function or change in risk score. Data was extracted and assessed for bias using the revised Cochrane risk-of-bias assessment tool.

resultsSeven studies were included. Participants' mean age ranged from 45.3 to 64.2 years. Interventions ranged from 10 weeks to 9.8 years and targeted between two and six dementia risk factors. There was a large variation in the type of outcome and statistical tests utilised across the included studies, impacting the ability to draw comparisons between the studies and draw conclusions regarding treatment effects. There was a high risk of bias in three of the studies and some concerns of bias in the other four studies. Two studies assessing dementia risk found a reduction in risk scores at their primary endpoint. None of the included studies found a statistically significant change in cognition from their interventions. This may be attributable in part to not assessing cognition prior to the interventions, limited risk factors being addressed, and the short follow-up/duration of the studies.

conclusionCurrent evidence for multidomain dementia risk-reduction interventions in mid-life is not definitive; however, given their substantive potential benefits and likely limited harms, they may be considered for implementation in clinical practice after further evaluation. Future trials that have longer follow-ups, target a broader range of dementia risk factors, and that use consistent outcome measures will be valuable. Strategies to maximise implementation of multidomain interventions and long-term effectiveness will enhance the evidence base for dementia prevention in primary care.

Indexed as

DementiaPrimary Health CareRisk Reduction BehaviorHumansMiddle AgedRisk Factors

Identifiers

PMID40335342
PMCPMC12434273

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.